Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Dermapharm Holding SECHIX:DMPD 73 3-Year Revenue Growth Rate is 4.40% as of Jun. 2026, which is 67% below its 10-year median of 13.50. GuruFocus rates CHIX:DMPD with a GF Score™ of 73/100 and a GF Value™ of €35.49 (Fairly Valued). The stock has 5 warning signs investors should review. Among 905 Drug Manufacturers companies, Dermapharm Holding SE ranks better than 52.71% on this metric.
During the past 12 months, Dermapharm Holding SE's average Revenue per Share Growth Rate was 2.40% per year.
During the past 3 years, the average Revenue per Share Growth Rate was 4.40% per year.
During the past 5 years, the average Revenue per Share Growth Rate was 8.00% per year.
During the past 10 years, the average Revenue per Share Growth Rate was 13.10% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Revenue per Share growth rate.
During the past 12 years, the highest 3-Year average Revenue per Share Growth Rate of Dermapharm Holding SE was 19.30% per year. The lowest was 4.40% per year. And the median was 13.50% per year.
Dermapharm Holding SE (CHIX:DMPd) 3-Year Revenue Growth Rate Explanation
Revenue per Share is the amount of Revenue per outstanding share of the company's stock.
Revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top. Revenue per share growth rate is used in calculating Predictability Rank, companies with more consistent revenue and earnings growth are ranked high with predictability.
Dermapharm Holding SE 3-Year Revenue Growth Rate Related Terms
CHIX:DMPD vs ZTS, UTHR, VTRS: 3-Year Revenue Growth Rate Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Dermapharm Holding SE's 3-Year Revenue Growth Rate, along with its competitors' market caps and 3-Year Revenue Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Dermapharm Holding SE 3-Year Revenue Growth Rate vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Dermapharm Holding SE's 3-Year Revenue Growth Rate distribution charts can be found below:
* The bar in red indicates where Dermapharm Holding SE's 3-Year Revenue Growth Rate falls into.
Dermapharm Holding SE 3-Year Revenue Growth Rate Calculation
This is the 3-year average growth rate of Revenue per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Revenue per Share growth rate.
What does a 3-Year Revenue Growth Rate of 4.40% mean?
Dermapharm Holding SE (CHIX:DMPD) has a 3-Year Revenue Growth Rate of 4.40% as of Jun. 2026. 3-Year Revenue Growth Rate is the 3-year average growth rate of Revenue per share. View historical data for Dermapharm Holding SE and its competitors. This is 67% below median its historical median of 13.50. Over the past decade, Dermapharm Holding SE's 3-Year Revenue Growth Rate has ranged from 4.40 to 19.30. According to the industry distribution chart, Dermapharm Holding SE ranks #428 out of 905 companies in the Drug Manufacturers industry, placing it in the top 47.3%.
Is Dermapharm Holding SE's 3-Year Revenue Growth Rate too high?
Dermapharm Holding SE's current 3-Year Revenue Growth Rate of 4.40% is 67% below median its 10-year median of 13.50. Over the past 10 years, this metric has ranged from a low of 4.40 to a high of 19.30. The Drug Manufacturers industry median 3-Year Revenue Growth Rate is 3.70. Dermapharm Holding SE's value of 4.40% is 18.9% above this industry median. Based on the distribution chart, Dermapharm Holding SE ranks #428 out of 905 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Dermapharm Holding SE has a GF Score™ of 73/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Dermapharm Holding SE's 3-Year Revenue Growth Rate compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Dermapharm Holding SE ranks #428 out of 905 companies for 3-Year Revenue Growth Rate. This puts Dermapharm Holding SE in the upper half of its industry. The industry median 3-Year Revenue Growth Rate is 3.70. Dermapharm Holding SE's value of 4.40% is 18.9% above this benchmark. Historically, Dermapharm Holding SE's own 3-Year Revenue Growth Rate has ranged from 4.40 to 19.30 over the past decade. While the company's 10-year median is 13.50 vs. the industry median of 3.70, Dermapharm Holding SE has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year Revenue Growth Rate for a Drug Manufacturers company?
The median 3-Year Revenue Growth Rate among Drug Manufacturers companies is 3.70, based on 905 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year Revenue Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year Revenue Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Dermapharm Holding SE's current 3-Year Revenue Growth Rate of 4.40% is 18.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year Revenue Growth Rate mean?
A high 3-Year Revenue Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year Revenue Growth Rate is the 3-year average growth rate of Revenue per share. View historical data for Dermapharm Holding SE and its competitors. For the Drug Manufacturers industry, the median 3-Year Revenue Growth Rate is 3.70 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Dermapharm Holding SE's current 3-Year Revenue Growth Rate is 4.40%, which is 67% below median its own 10-year median of 13.50. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Dermapharm Holding SE stock overvalued right now?
Based on GuruFocus' analysis, Dermapharm Holding SE (CHIX:DMPD) is currently considered Fairly Valued. The stock's GF Value™ is €35.49, compared to a current price of €38.63 — trading 8.8% above its estimated fair value. The current 3-Year Revenue Growth Rate is 4.40%, which is 67% below median its 10-year median of 13.50 and 18.9% above the Drug Manufacturers industry median of 3.70. Dermapharm Holding SE's overall GF Score™ is 73/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year Revenue Growth Rate calculated?
3-Year Revenue Growth Rate is calculated from a company's financial statements. For Dermapharm Holding SE (CHIX:DMPD), the current 3-Year Revenue Growth Rate is 4.40% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Dermapharm Holding SE (CHIX:DMPD) Overvalued in 2026?
Based on GuruFocus' analysis, Dermapharm Holding SE stock appears to be overvalued.
The current stock price of €38.63 is trading 8.8% above its estimated GF Value™ of €35.49.
GuruFocus considers Dermapharm Holding SE to be Fairly Valued.
Key valuation signals for CHIX:DMPD:
3-Year Revenue Growth Rate: 4.40% (67% below median its 10-year median of 13.50)
GF Value™: €35.49 vs. price of €38.63 (8.8% above fair value)
Industry Position: 18.9% above the Drug Manufacturers median (#428 of 905)
No single metric tells the full story. See the CHIX:DMPD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Dermapharm Holding SE manufactures patent-free branded pharmaceuticals for selected therapy fields, over-the-counter drugs, and natural remedies. The portfolio of the company includes cosmetics, nutritional supplements, and diet and medical devices. Business operating segments include Branded pharmaceuticals, which drive key revenue, Other healthcare products, and Parallel import business. The Branded pharmaceuticals segment covers numerous product areas through a wide variety of items sold under reputable brand names.
73GF Score
Get the complete analysis for CHIX:DMPD
3-Year Revenue Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CHIX:DMPD has been successfully added to your 
